GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells 46,551 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 46,551 shares of the stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $95.62, for a total value of $4,451,206.62. Following the transaction, the chief executive officer now directly owns 48,314 shares of the company's stock, valued at approximately $4,619,784.68. The trade was a 49.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total transaction of $96,416.32.
• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08.

GeneDx Stock Down 4.5 %

Shares of NASDAQ WGS traded down $3.98 during trading hours on Tuesday, hitting $84.59. The stock had a trading volume of 860,363 shares, compared to its average volume of 646,225. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The company has a market capitalization of $2.37 billion, a P/E ratio of -43.16 and a beta of 1.91. The firm's 50-day moving average price is $87.87 and its two-hundred day moving average price is $75.16. GeneDx Holdings Corp. has a 52 week low of $8.53 and a 52 week high of $115.60.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of GeneDx by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock worth $77,337,000 after buying an additional 156,768 shares during the last quarter. Summit Partners Public Asset Management LLC lifted its position in GeneDx by 336.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company's stock worth $58,073,000 after acquiring an additional 582,619 shares during the last quarter. William Blair Investment Management LLC bought a new stake in GeneDx during the fourth quarter valued at about $51,496,000. Lord Abbett & CO. LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at about $48,458,000. Finally, Fred Alger Management LLC increased its stake in shares of GeneDx by 38.5% in the fourth quarter. Fred Alger Management LLC now owns 546,054 shares of the company's stock worth $41,970,000 after purchasing an additional 151,824 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. TD Cowen upped their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.